A326030 Stock Overview
A pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A326030 from our risk checks.
SK Biopharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩77,000.00 |
| 52 Week High | ₩104,800.00 |
| 52 Week Low | ₩72,700.00 |
| Beta | 1.07 |
| 11 Month Change | -8.22% |
| 3 Month Change | -16.76% |
| 1 Year Change | -5.64% |
| 33 Year Change | -37.40% |
| 5 Year Change | n/a |
| Change since IPO | -39.37% |
Recent News & Updates
Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?
May 22
SK Biopharmaceuticals Co., Ltd. (KRX:326030) Not Lagging Industry On Growth Or Pricing
Apr 09Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?
Feb 27Recent updates
Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?
May 22SK Biopharmaceuticals Co., Ltd. (KRX:326030) Not Lagging Industry On Growth Or Pricing
Apr 09Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?
Feb 27We're Not Worried About SK Biopharmaceuticals' (KRX:326030) Cash Burn
Mar 12Shareholder Returns
| A326030 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -0.5% | 0.1% | 0.02% |
| 1Y | -5.6% | 6.7% | 5.7% |
Return vs Industry: A326030 underperformed the KR Pharmaceuticals industry which returned 6.7% over the past year.
Return vs Market: A326030 underperformed the KR Market which returned 5.7% over the past year.
Price Volatility
| A326030 volatility | |
|---|---|
| A326030 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.2% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A326030 has not had significant price volatility in the past 3 months.
Volatility Over Time: A326030's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 252 | Dong Hoon Lee | www.skbp.com |
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder.
SK Biopharmaceuticals Co., Ltd. Fundamentals Summary
| A326030 fundamental statistics | |
|---|---|
| Market cap | ₩6.17t |
| Earnings (TTM) | -₩17.68b |
| Revenue (TTM) | ₩408.08b |
14.8x
P/S Ratio-341.0x
P/E RatioIs A326030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A326030 income statement (TTM) | |
|---|---|
| Revenue | ₩408.08b |
| Cost of Revenue | ₩42.09b |
| Gross Profit | ₩365.99b |
| Other Expenses | ₩383.67b |
| Earnings | -₩17.68b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -225.79 |
| Gross Margin | 89.69% |
| Net Profit Margin | -4.33% |
| Debt/Equity Ratio | 50.4% |
How did A326030 perform over the long term?
See historical performance and comparison